Lala Soltanova

Lala Soltanova

Auto-generated profile, based on publicly available information

Lala Soltanova

Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
IMIlkin Muradov
Ilkin Muradov
SŞSerdar Şahin
Serdar Şahin
SUSerhat Uysal
Serhat Uysal
CScem sulu
cem sulu
PGPelinsu Gunebakan
Pelinsu Gunebakan
PKPınar Kadıoğlu
Pınar Kadıoğlu

8 March 2026 in Clinical Endocrinology
Verified
Journal Article
Closed access
IMIlkin Muradov
Ilkin Muradov
SŞSerdar Şahin
Serdar Şahin
SASumeyye Akpinar
Sumeyye Akpinar
ATAli Tunc
Ali Tunc
BKbanu betül kocaman
banu betül kocaman
PKPınar Kadıoğlu
Pınar Kadıoğlu

26 December 2025 in Pituitary
Verified
Journal Article
Closed access
PDF file
BKbanu betül kocaman
banu betül kocaman
YCYusuf Cicek
Yusuf Cicek
SŞSerdar Şahin
Serdar Şahin
ADAhmet Burhan Dogan
Ahmet Burhan Dogan
SUSerhat Uysal
Serhat Uysal
PKPınar Kadıoğlu
Pınar Kadıoğlu

10 July 2026 in Endocrine
Verified
Journal Article
Closed access
PDF file
IMIlkin Muradov
Ilkin Muradov
SUSerhat Uysal
Serhat Uysal
BKbanu betül kocaman
banu betül kocaman
LSLala Soltanova
Lala Soltanova
OKOgulcan Karali
Ogulcan Karali
EDEmre Durcan
Emre Durcan

3 August 2026 in Endocrinology Research and Practice
Verified
Journal Article
Open access
PDF file
ASAysel Selimzade
Aysel Selimzade
BKbanu betül kocaman
banu betül kocaman
IMIlkin Muradov
Ilkin Muradov
LSLala Soltanova
Lala Soltanova
SŞSerdar Şahin
Serdar Şahin
MGMustafa Sait Gönen
Mustafa Sait Gönen
Objective: This study aimed to investigate the impact of thyroid-stimulating hormone (TSH) suppression therapy on psychological outcomes and quality of life in patients with differentiated thyroid carcinoma (DTC), with particular focus on anxiety, depression, hypomania, and related hormonal parameters. Methods: A total of 87 adult patients with DTC receiving levothyroxine therapy were evaluated. Participants were grouped according to their TSH levels: <0.1, 0.1-0.5, and 0.6-4.2 mIU/L. Psychometric evaluations included the Beck Anxiety Inventory, Beck Depression Inventory, Hypomania Checklist-32, and Quality of Life Short Form (SF-36) Quality of Life Scale. Thyroid function tests and clinical parameters were recorded. Comparative, correlational, and multivariable regression analyses were performed. Results: No significant differences were found in psychometric scores or SF-36 subdomains among the TSH-based groups. However, a weak positive correlation was identified between TSH levels and anxiety scores (r = 0.175, P = .044), while T3 levels were inversely correlated with depression scores (r = −0.216, P = .045). These exploratory associations did not remain statistically significant in multivariable linear and logistic regression analyses. No independent associations were identified between TSH categories or thyroid hormone levels and psychological outcomes. Conclusion: The TSH suppression therapy does not appear to significantly affect quality of life or mood-related symptoms in a categorical manner. Although these associations were attenuated in regression analyses, subtle relationships among TSH, T3, and psychological parameters may still exist, suggesting that psychological outcomes are influenced by multiple clinical and psychosocial factors. These findings support the need for individualized treatment strategies that consider both oncologic control and patient well-being. Cite this article as: Selimzade A, Kocaman BB, Muradov I, et al. TSH suppression therapy and its association with anxiety, depression, hypomania, and quality of life in differentiated thyroid cancer. Endocrinol Res Pract. Published online August 1, 2026. doi: 10.5152/erp.2026.26918.

8 December 2025 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
LSLala Soltanova
Lala Soltanova
BSBurcu Saglamer
Burcu Saglamer
EDEmre Durcan
Emre Durcan
SUSerhat Uysal
Serhat Uysal
IMIlkin Muradov
Ilkin Muradov
TDTaner Damci
Taner Damci
Objective: Daily step count is widely accepted as a valuable indicator of physical activity level. The study aimed to test whether it was possible to establish and/or increase patients' connectedness with the pedometer data in their smartphones and smartwatches through a short reminder. Methods: The study included 70 patients whose daily average step count was checked, who provided good glycemic control and whose treatment would not be changed (HbA1c < 7.5%). Demographic and laboratory data of the patients, average step counts in the last 6 months, and smartphone models were recorded, and these data were compared with the data after 6 months. Results: The study included 70 diabetic patients, 30 women and 40 men. The mean number of steps increased from 5587.8 plus/minus 2959 at baseline to 6219 plus/minus 3001 after 6 months. The number of steps increased from 4692 plus/minus 2402 to 6502 plus/minus 2813 in 47 (62%) patients with brief reminder (P < .001). There is a correlation between the increase in the number of steps and the decrease in HbA1c (P < .05). Conclusion: This study demonstrates that a short reminder recited by physicians during the diabetes outpatient clinics visits aimed at increasing connectedness to smartphone/watch daily step count data leads to an increase in daily step count in most of the patients over 6 months. The increase in the daily step count correlated significantly with a decrease in HbA1c levels.